Tiziana Life Sciences Ltd
NASDAQ:TLSA
Intrinsic Value
Tiziana Life Sciences Ltd. engages in the research and development of biotechnological and pharmaceutical products. [ Read More ]
The intrinsic value of one
TLSA
stock under the Base Case scenario is
0.1963
USD.
Compared to the current market price of 0.7901 USD,
Tiziana Life Sciences Ltd
is
Overvalued by 75%.
Tiziana Life Sciences Ltd's market capitalization is 80.8m USD.
TLSA stock price is 0.7901 USD.
TLSA stock (0.1963 USD) is 75% less than its price (0.7901 USD).
TLSA stock (0.1963 USD) is 75% less than its price (0.7901 USD). Open DCF Valuation
TLSA. Open Relative Valuation
TLSA has upside potential of 287% compared to the average analyst price target.
Open Wall St Estimates
TLSA has negative Free Cash Flow for the last twelve months.
TLSA has negative Operating Income for the last twelve months.
TLSA has negative Net Income for the last twelve months.
TLSA's ROE (Return on Equity) has significantly increased in the last 3 years from -92% to -51%, and is approaching profitability.
TLSA's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 10 565% to -518%.
TLSA's ROE (Return on Equity) for the past 12 months is negative and is equal to -51%.
TLSA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -518%.
TLSA's Altman Z-Score is very high and is equal to 3.89.
TLSA's short-term assets (24m USD) exceed its short-term liabilties (7m USD).
TLSA's long-term assets (26m USD) exceed its long-term liabilties (7m USD).
TLSA's D/E (Debt to Equity) is very low and is equal to 0.01.
TLSA has negative three-year average ROE (Return on Equity): -114%. The company is not efficient at transforming stockholders' equity into net income.
TLSA has very high three-year average ROIC (Return on Invested Capital): 756%. The company is very efficient at using invested capital to generate operating income.
TLSA has negative Net Debt. This means that the company has more cash and short-term investments (18m USD) than debt (240k USD).
Valuation Backtest
Tiziana Life Sciences Ltd
Run backtest to discover the historical profit from buying and selling
TLSA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Tiziana Life Sciences Ltd
Balance Sheet Decomposition
Tiziana Life Sciences Ltd
| Current Assets | 24.3m |
| Cash & Short-Term Investments | 18.1m |
| Receivables | 6m |
| Other Current Assets | 170k |
| Non-Current Assets | 2.2m |
| Long-Term Investments | 1.8m |
| PP&E | 390k |
| Current Liabilities | 6.7m |
| Accounts Payable | 5m |
| Accrued Liabilities | 1.6m |
| Other Current Liabilities | 130k |
| Non-Current Liabilities | 250k |
| Long-Term Debt | 240k |
| Other Non-Current Liabilities | 10k |
Earnings Waterfall
Tiziana Life Sciences Ltd
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-14.6m
USD
|
|
Operating Income
|
-14.6m
USD
|
|
Other Expenses
|
-810k
USD
|
|
Net Income
|
-15.4m
USD
|
Free Cash Flow Analysis
Tiziana Life Sciences Ltd
TLSA Profitability Score
Profitability Due Diligence
Tiziana Life Sciences Ltd's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Tiziana Life Sciences Ltd's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
TLSA Solvency Score
Solvency Due Diligence
Tiziana Life Sciences Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Score
Tiziana Life Sciences Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TLSA Price Targets Summary
Tiziana Life Sciences Ltd
According to Wall Street analysts, the average 1-year price target for
TLSA
is 3.06 USD
with a low forecast of 3.03 USD and a high forecast of 3.15 USD.
Shareholder Return
TLSA Price
Tiziana Life Sciences Ltd
| Average Annual Return | -4.27% |
| Standard Deviation of Annual Returns | 88.67% |
| Max Drawdown | -94% |
| Market Capitalization | 80.8m USD |
| Shares Outstanding | 100 307 800 |
| Percentage of Shares Shorted | 0.52% |
TLSA News
Last Important Events
Tiziana Life Sciences Ltd
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Tiziana Life Sciences Ltd
Company Profile
Tiziana Life Sciences Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Tiziana Life Sciences Ltd. engages in the research and development of biotechnological and pharmaceutical products. The firm is focused on the discovery and development of molecules and related diagnostics to treat unmet medical needs in oncology and immunology. Its lead product candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501), and Milciclib TZLS-201. Foralumab (TZLS-401) is a fully human engineered anti-human cluster of differentiation 3 (CD3) monoclonal antibody (mAb). Foralumab is developed for the treatment of neurodegenerative diseases such as progressive Multiple Sclerosis (MS), and Crohn’s disease. The Anti IL-6R mAb (TZLS-501) is a fully human engineered mAb targeting the interleukin-6 receptor (IL-6R). Anti-IL-6R antibody can be used in combination with Foralumab or other anti-inflammatory and anti-infective agents as therapy for COVID-19 and oncology indications. The firm has developed Milciclib TZLS-201 for the treatment of hepatocellular carcinoma (HCC).
Contact
IPO
Employees
Officers
The intrinsic value of one
TLSA
stock under the Base Case scenario is
0.1963
USD.
Compared to the current market price of 0.7901 USD,
Tiziana Life Sciences Ltd
is
Overvalued by 75%.
You don't have any saved screeners yet
